150 related articles for article (PubMed ID: 23278696)
1. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Yokooji T; Kawabe Y; Mori N; Murakami T
J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
[TBL] [Abstract][Full Text] [Related]
2. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
[TBL] [Abstract][Full Text] [Related]
3. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
Horikawa M; Kato Y; Sugiyama Y
Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
5. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Guo S; Zhang X; Gan L; Zhu C; Gan Y
J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
[TBL] [Abstract][Full Text] [Related]
6. Modulated pharmacokinetics and increased small intestinal toxicity of methotrexate in bilirubin-treated rats.
Yokooji T; Mori N; Murakami T
J Pharm Pharmacol; 2011 Feb; 63(2):206-13. PubMed ID: 21235584
[TBL] [Abstract][Full Text] [Related]
7. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
8. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
Maeda Y; Hamada A; Sanematsu E; Sasaki JI; Yokoo K; Hira A; Saito H
Cancer Chemother Pharmacol; 2010 Apr; 65(5):953-9. PubMed ID: 19697031
[TBL] [Abstract][Full Text] [Related]
10. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
[TBL] [Abstract][Full Text] [Related]
11. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
12. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
[TBL] [Abstract][Full Text] [Related]
13. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
15. The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.
Chowbay B; Sharma A; Zhou QY; Cheung YB; Lee EJ
Oncol Rep; 2003; 10(3):745-51. PubMed ID: 12684653
[TBL] [Abstract][Full Text] [Related]
16. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Mick R; Gupta E; Vokes EE; Ratain MJ
J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
[TBL] [Abstract][Full Text] [Related]
17. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
[TBL] [Abstract][Full Text] [Related]
18. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
[TBL] [Abstract][Full Text] [Related]
19. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
20. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
Wang X; Rao Z; Qin H; Zhang G; Ma Y; Jin Y; Han M; Shi A; Wang Y; Wu X
Biopharm Drug Dispos; 2016 Oct; 37(7):421-432. PubMed ID: 27510985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
